280M people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey. OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers.
The project focuses on the microbiota–brain axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks.

OPADE project

Org chart

Teams

Offices